| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
5-HT1A receptor (pKi = 10.23) [1]
5-HT1B receptor (pIC50 = 5.12) [1] 5-HT2A receptor (pIC50 < 5) [1] |
|---|---|
| ln Vitro |
F14679 induced a large-magnitude Ca2+ response in CHO-K1 cells transiently expressing the human 5-HT1A receptor, with Emax = 87 ± 3% (relative to 10 μM 5-HT) and pEC50 = 7.33 ± 0.16. This response was similar in magnitude to that of 5-HT and 5-CT. [1]
In contrast, prototypical 5-HT1A agonists (buspirone, 8-OH-DPAT, ipsapirone, flesinoxan, eptapirone) showed virtually no Ca2+ response (Emax ≤ 5%). [1] F14679 stimulated [35S]GTPγS binding in membranes of CHO-K1 cells stably expressing the human 5-HT1A receptor, with Emax = 93 ± 6% (vs. 10 μM 5-HT) and pEC50 = 9.21 ± 0.15. [1] In membranes of C6-glial cells stably expressing the human 5-HT1A receptor, F14679 produced a maximal [35S]GTPγS binding response of 61% (relative to 5-HT) with pEC50 = 8.31. [1] In HeLa cells expressing the human 5-HT1A receptor, F14679 induced a cAMP response with Emax = 110% (vs. 5-HT) and pEC50 = 8.70. [1] |
| Enzyme Assay |
[35S]GTPγS binding responses were determined using membrane preparations of CHO-K1 or C6-glial cells stably transfected with a recombinant human 5-HT1A receptor. Incubation mixtures contained membrane preparation (20-40 μg protein), test ligand, and 30 μM GDP in a total volume of 0.4 mL. After 30 min incubation at 25°C, 0.05 mL of 0.5 nM [35S]GTPγS was added and incubated for another 30 min. Reactions were terminated by adding 3 mL of ice-cold 20 mM HEPES (pH 7.4) containing 3 mM MgCl2, followed by rapid filtration. Maximal stimulation was defined in the presence of 10 μM 5-HT. Emax values were expressed as percentage of the response obtained with 10 μM 5-HT. [1]
Binding affinities for 5-HT1B and 5-HT2A receptor subtypes were determined as described previously (Koek et al., 1998). F14679 showed pIC50 = 5.12 at 5-HT1B receptors and pIC50 < 5 at 5-HT2A receptors. [1] |
| Cell Assay |
Intracellular Ca2+ responses were measured in CHO-K1 cells transiently transfected with human 5-HT1A receptor. Cells were loaded with 2 μM Fluo-3 fluorescent calcium indicator dye for 1 hour. Test ligands including F14679 were assayed at concentrations between 1 nM and 10 μM. Fluorescent readings were taken every 2 seconds for the first 3 minutes using a fluorometric image plate reader. Emax values were defined as the ligand‘s maximal high-magnitude Ca2+ response as percentage of that obtained with 10 μM 5-HT. pEC50 values correspond to the ligand concentration at which 50% of its own maximal high-magnitude Ca2+ response was measured. For F14679, Emax = 87 ± 3% and pEC50 = 7.33 ± 0.16. [1]
For antagonist studies, cells were preincubated with antagonist for 10 min before 5-HT addition, and Ca2+ response was recorded for 3 min. Antagonist potency (pIC50) was defined as the concentration required to antagonize 50% of the Ca2+ response induced by 1 μM 5-HT, calculated as the difference in surface area between 5-HT and ligand conditions. [1] cAMP responses were monitored in transfected HeLa cells as previously described (Pauwels et al., 1993). F14679 showed Emax = 110% (vs. 5-HT) and pEC50 = 8.70. [1] |
| References | |
| Additional Infomation |
F14679 is a representative ligand of a new chemical class (5-methyl-pyridin-2-ylmethyl amine derivatives) that combines both high efficacy and selectivity for 5-HT1A receptors. [1]
In contrast to 5-CT (a non-selective high-efficacy 5-HT1A ligand), F14679 is highly selective for the 5-HT1A receptor, showing no significant binding to 5-HT1B and 5-HT2A receptors. [1] The Ca2+ response data indicate an atypical pharmacological profile for 5-HT1A receptor ligands: F14679 (together with F13640 and 5-CT) induced a high-magnitude Ca2+ response similar to 5-HT, whereas prototypical partial agonists (buspirone, 8-OH-DPAT, ipsapirone, flesinoxan, eptapirone) were inactive. This suggests that F14679 may selectively induce responses that are not achieved with other ligands. [1] |
| Molecular Formula |
C21H25CLF2N4O
|
|---|---|
| Molecular Weight |
422.899210691452
|
| Exact Mass |
422.168
|
| CAS # |
208109-38-0
|
| Related CAS # |
F 13714 fumarate;208109-39-1
|
| PubChem CID |
9802369
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
547
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(N=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F)NC
|
| InChi Key |
QILKJZOYDVAGPZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H25ClF2N4O/c1-14-3-5-16(27-19(14)25-2)12-26-13-21(24)7-9-28(10-8-21)20(29)15-4-6-18(23)17(22)11-15/h3-6,11,26H,7-10,12-13H2,1-2H3,(H,25,27)
|
| Chemical Name |
(3-chloro-4-fluorophenyl)-[4-fluoro-4-[[[5-methyl-6-(methylamino)pyridin-2-yl]methylamino]methyl]piperidin-1-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3646 mL | 11.8231 mL | 23.6463 mL | |
| 5 mM | 0.4729 mL | 2.3646 mL | 4.7293 mL | |
| 10 mM | 0.2365 mL | 1.1823 mL | 2.3646 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
